

In the Claims

1-91 (canceled).

92 (new). An isolated polypeptide having chemotactic activity and comprising:

- (a) SEQ ID NO: 2; or
- (b) the mature form of the polypeptide of SEQ ID NO: 2.

93 (new). The isolated polypeptide of claim 92, wherein said polypeptide comprises SEQ ID NO: 2.

94 (new). The isolated polypeptide of claim 92, wherein said polypeptide comprises the mature form of the polypeptide of SEQ ID NO: 2.

95 (new). The polypeptide of claim 92, wherein said polypeptide further comprises a molecule chosen from radioactive labels, fluorescent labels, biotin or cytotoxic agents.

96 (new). The polypeptide of claim 93, wherein said polypeptide further comprises a molecule chosen from radioactive labels, fluorescent labels, biotin or cytotoxic agents.

97 (new). The polypeptide of claim 94, wherein said polypeptide further comprises a molecule chosen from radioactive labels, fluorescent labels, biotin or cytotoxic agents.

98 (new). A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a polypeptide having chemotactic activity and comprising:

- (a) SEQ ID NO: 2; or
- (b) the mature form of the polypeptide of SEQ ID NO: 2.

99 (new). The pharmaceutical composition of claim 98, wherein said polypeptide comprises SEQ ID NO: 2.

100 (new). The pharmaceutical composition of claim 98, wherein said polypeptide comprises the mature form of the polypeptide of SEQ ID NO: 2.

101 (new). The pharmaceutical composition of claim 98, wherein said polypeptide further comprises a molecule chosen from radioactive labels, fluorescent labels, biotin or cytotoxic agents.

102 (new). The pharmaceutical composition of claim 98, wherein said polypeptide further comprises a molecule chosen from radioactive labels, fluorescent labels, biotin or cytotoxic agents.

103 (new). The pharmaceutical composition of claim 98, wherein said polypeptide further comprises a molecule chosen from radioactive labels, fluorescent labels, biotin or cytotoxic agents.